Guggenheim Capital LLC Exelixis, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 111,807 shares of EXEL stock, worth $3.78 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

111,807

Previous 125,464 10.89%

Holding current value

$3.78 Million

Previous $2.82 Million 2.91%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$21.96 - $27.6 $299,907 - $376,933	-13,657 Reduced 10.89%	111,807 $2.9 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $3.05 Million - $3.56 Million	-150,133 Reduced 54.48%	125,464 $2.82 Million
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $1.88 Million - $2.23 Million	93,063 Added 50.98%	275,597 $6.54 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $733,328 - $919,232	-38,095 Reduced 17.27%	182,534 $4.38 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $113,535 - $135,598	-5,963 Reduced 2.63%	220,629 $4.82 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $171,034 - $192,778	-9,413 Reduced 3.99%	226,592 $4.33 Million
Q1 2023 May 10, 2023	SELL	$16.3 - $19.41 $6,047 - $7,201	-371 Reduced 0.16%	236,005 $4.58 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $14,301 - $16,624	-956 Reduced 0.4%	236,376 $3.79 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $48,952 - $69,526	-3,122 Reduced 1.3%	237,332 $3.72 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $194,333 - $258,071	-11,143 Reduced 4.43%	240,454 $5.01 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $215,514 - $286,888	-12,655 Reduced 4.79%	251,597 $5.7 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $1.15 Million - $1.59 Million	-72,608 Reduced 21.55%	264,252 $4.83 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $343,587 - $445,610	21,079 Added 6.68%	336,860 $7.12 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $539,864 - $768,742	30,076 Added 10.53%	315,781 $5.75 Million
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $42,394 - $52,079	2,065 Added 0.73%	285,705 $6.45 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $618,768 - $834,445	33,647 Added 13.46%	283,640 $5.69 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $1.04 Million - $1.35 Million	-50,164 Reduced 16.71%	249,993 $6.11 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $561,829 - $935,926	34,133 Added 12.83%	300,157 $7.13 Million
Q1 2020 Jun 02, 2020	SELL	$14.46 - $21.8 $541,584 - $816,497	-37,454 Reduced 12.34%	266,024 $4.58 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $1.38 Million - $1.72 Million	90,947 Added 42.79%	303,478 $5.35 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $107,176 - $137,304	-6,062 Reduced 2.77%	212,531 $3.76 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $513,589 - $671,492	-27,131 Reduced 11.04%	218,593 $4.67 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $34,613 - $43,726	1,766 Added 0.72%	245,724 $5.85 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $1.7 Million - $2.71 Million	-124,264 Reduced 33.75%	243,958 $4.8 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $44,880 - $63,347	2,828 Added 0.77%	368,222 $6.53 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $2.74 Million - $3.32 Million	147,829 Added 67.95%	365,394 $7.87 Million
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $389,995 - $561,487	17,607 Added 8.81%	217,565 $4.82 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $2.09 Million - $2.67 Million	-86,326 Reduced 30.15%	199,958 $6.08 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $6.68 Million - $8.37 Million	286,284	286,284 $6.94 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Exelixis, Inc. Transaction History